Piflufolastat F-18

From WikiProjectMed
Jump to navigation Jump to search

Piflufolastat F-18
Piflufolastat F-18 v01.svg
Names
Trade namesPylarify
Other names18F-DCFPyL
Clinical data
Drug classRadiopharmaceutical[1]
Main usesProstate cancer positron emission tomography (PET) imaging[2]
Side effectsHeadache, altered taste, tiredness[2]
Routes of
use
Intravenous
Typical dose333 MBq (9 mCi)[2]
External links
US NLMPiflufolastat F-18
Legal
License data
Legal status
Chemical and physical data
FormulaC18H23[18F]N4O8
Molar mass441.4 g/mol
3D model (JSmol)
  • OC(=O)CC[C@H](NC(=O)N[C@@H](CCCCNC(=O)C1=CC=C([18F])N=C1)C(O)=O)C(O)=O
  • InChI=1S/C18H23FN4O8/c19-13-6-4-10(9-21-13)15(26)20-8-2-1-3-11(16(27)28)22-18(31)23-12(17(29)30)5-7-14(24)25/h4,6,9,11-12H,1-3,5,7-8H2,(H,20,26)(H,24,25)(H,27,28)(H,29,30)(H2,22,23,31)/t11-,12-/m0/s1/i19-1
  • Key:OLWVRJUNLXQDSP-MVBOSPHXSA-N

Piflufolastat F-18, sold under the brand name Pylarify, is a radioactive diagnostic agent used in positron emission tomography (PET) imaging.[2] Specifically it is used to image prostate cancer that is prostate-specific membrane antigen (PSMA) positive to look for spread or recurrence.[2] It is given by injection into a vein.[2]

Common side effects include headache, altered taste, and tiredness.[2] Other side effects may include allergic reactions and radiation exposure.[2]

Piflufolastat F-18 was approved for medical use in the United States in 2021.[2] It is not approved in either Europe or the United Kingdom as of 2022.[1]

Medical uses

Piflufolastat F-18 is indicated for people with suspected prostate cancer metastasis (when cancer cells spread from the place where they first formed to another part of the body) who are potentially curable by surgery or other therapy.[2][3] Piflufolastat F-18 is also indicated for people with suspected prostate cancer recurrence based on elevated serum prostate-specific antigen (PSA) levels.[2][3]

Dosage

The typical dose is 333 MBq (9 mCi) 60 min before imaging.[2]

History

The safety and efficacy of piflufolastat F-18 were evaluated in two prospective clinical trials with a total of 593 men with prostate cancer who each received one injection of piflufolastat F-18.[3] In the first trial, a cohort of 268 participants with biopsy-proven prostate cancer underwent PET/CT scans performed with piflufolastat F-18.[3] These participants were candidates for surgical removal of the prostate gland and pelvic lymph nodes and were considered at higher risk for metastasis.[3] Among the participants who proceeded to surgery, those with positive readings in the pelvic lymph nodes on piflufolastat F-18 PET had a clinically important rate of metastatic cancer confirmed by surgical pathology.[3]

The second trial enrolled 208 participants who had rising serum PSA levels after initial prostate surgery or other definitive therapy, and thus had biochemical evidence of recurrent prostate cancer.[3] Prior to a single piflufolastat F-18 PET/CT scan, all of these participants had baseline conventional imaging performed that did not show definite spread of prostate cancer.[3] Piflufolastat F-18 PET detected at least one positive lesion in at least one body region (bone, prostate bed, pelvic lymph node, other lymph nodes, or soft tissue) in 60% of these participants.[3] In participants with positive piflufolastat F-18 PET readings who had correlative tissue pathology from biopsies, results from baseline or follow-up imaging by conventional methods, or serial PSA levels available for comparison, local recurrence or metastasis of prostate cancer was confirmed in an estimated 85% to 87% of cases, depending on the reader.[3] Thus, the second trial demonstrated that piflufolastat F-18 PET can detect sites of disease in participants with biochemical evidence of recurrent prostate cancer, thereby providing important information that may impact the approach to therapy.[3]

The U.S. Food and Drug Administration (FDA) granted approval of Pylarify to Progenics Pharmaceuticals, Inc.[3] It is the second PSMA-targeted PET imaging drug approved by the U.S. Food and Drug Administration (FDA).[3] The first approved PSMA-targeted PET imaging drug is Ga 68 PSMA-11.[3]

References

  1. 1.0 1.1 "Fluorine-18-DCFPyL". SPS - Specialist Pharmacy Service. 26 December 2019. Retrieved 29 October 2022.
  2. 2.00 2.01 2.02 2.03 2.04 2.05 2.06 2.07 2.08 2.09 2.10 2.11 2.12 "Pylarify- piflufolastat f-18 injection". DailyMed. Archived from the original on 13 September 2021. Retrieved 12 September 2021.
  3. 3.00 3.01 3.02 3.03 3.04 3.05 3.06 3.07 3.08 3.09 3.10 3.11 3.12 3.13 "FDA approves PSMA-targeted imaging drug for men with prostate cancer". U.S. Food and Drug Administration (FDA). 27 May 2021. Archived from the original on 11 September 2021. Retrieved 12 September 2021. Public Domain This article incorporates text from this source, which is in the public domain.

 This article incorporates public domain material from the United States Department of Health and Human Services website http://www.fda.gov.

External links

Identifiers:
  • "Piflufolastat F18". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on 18 February 2022. Retrieved 1 September 2022.
  • "SDS Data Sheet" (PDF). Archived (PDF) from the original on 30 April 2022. Retrieved 1 September 2022.
  • Clinical trial number NCT02981368 for "Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer (OSPREY)" at ClinicalTrials.gov
  • Clinical trial number NCT03739684 for "Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer (CONDOR)" at ClinicalTrials.gov